U.S. Industrial REITs Stock News

NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$866.56 million to a net loss of US$2.81 million while still beating analyst expectations on both revenue and earnings per share. The company also released positive 24-month interim data for Huntington’s disease therapy votoplam and raised its 2026 product revenue guidance, underscoring how a strong Sephience launch and advancing...
NYSE:SBSI
NYSE:SBSIBanks

A Look At Southside Bancshares (SBSI) Valuation After Q1 Earnings Growth And Dividend Reaffirmation

Southside Bancshares (SBSI) drew fresh attention after reporting first quarter 2026 results and affirming a quarterly dividend of $0.36 per share, pairing earnings information with a continued cash return to shareholders. See our latest analysis for Southside Bancshares. The recent first quarter update and confirmed dividend come after a steadily improving share price. The 1 month share price return was 5.12% and the year to date share price return was 10.51%, alongside a 1 year total...
NYSE:EE
NYSE:EEOil and Gas

A Look At Excelerate Energy (EE) Valuation After Recent Share Price Volatility

Why Excelerate Energy is on investors’ radar Excelerate Energy (EE) has drawn fresh attention after recent trading left the stock with a year to date total return of 19.58% and a 1 year total return of 17.62%, against a last close of US$33.89. See our latest analysis for Excelerate Energy. Recent trading has been choppy, with the share price up 2.5% on the day to US$33.89 but down over 13% on a 3 month share price return. This compares with a stronger 3 year total shareholder return of 62.2%,...
NasdaqCM:UFPT
NasdaqCM:UFPTMedical Equipment

A Look At UFP Technologies (UFPT) Valuation After Q1 2026 Earnings And Acquisition Plans

UFP Technologies (UFPT) just paired its Q1 2026 earnings with a clear push on acquisitions, as management highlighted a full deal pipeline, ongoing bids, and a disciplined filter on price, culture, and fit. See our latest analysis for UFP Technologies. The Q1 2026 earnings update and acquisition commentary have arrived alongside a sharp swing in sentiment, with a 19.7% 7 day share price return and a 14.6% 30 day share price return partly offsetting a 13.8% 90 day decline and leaving the 1...
NasdaqGS:LECO
NasdaqGS:LECOMachinery

Assessing Lincoln Electric (LECO) Valuation After Strong Q1 Earnings And Renewed Investor Interest

Q1 earnings spark fresh interest in Lincoln Electric Holdings (LECO) Lincoln Electric Holdings (LECO) is back on investor radar after reporting first quarter sales of US$1,121.43 million and net income of US$136.38 million, both above the prior year period. See our latest analysis for Lincoln Electric Holdings. The earnings beat comes after a mixed share price run, with the stock up 11.22% year to date and delivering a 40.97% total shareholder return over one year. However, the 90 day share...
NYSE:PLGO
NYSE:PLGOInsurance

Will Dividend Debut and CVC Exit Change Fidelis Insurance Holdings' (FIHL) Ownership and Capital Story?

Fidelis Insurance Holdings Limited recently declared a quarterly dividend of US$0.15 per share, payable on June 26, 2026, following shareholder approval of bye-law amendments and ahead of its rebrand to Pelagos Insurance Capital Limited on May 11, 2026. Alongside this cash return, the company completed the repurchase of all remaining shares held by former principal shareholder CVC Falcon Holdings Limited, simplifying its ownership structure and removing a private equity governance...
NasdaqGS:CRNX
NasdaqGS:CRNXPharmaceuticals

Crinetics Pharmaceuticals (CRNX) Is Up 12.1% After PALSONIFY EU Nod And Surging Q1 Revenue Shift

In early May 2026, Crinetics Pharmaceuticals reported first-quarter revenue of about US$10.73 million, up sharply from roughly US$0.36 million a year earlier, alongside a wider net loss of about US$127.85 million and basic loss per share of US$1.23. Shortly before these results, the European Commission approved PALSONIFY (paltusotine) as the first once-daily oral therapy for adult acromegaly across the EU and EEA, reinforcing Crinetics’ shift into a commercial-stage rare disease business...
NYSE:RYZ
NYSE:RYZMetals and Mining

Will Ryerson's (RYZ) Q1 Profit Return and ESOP Shelf Offering Recast Its Equity Strategy Narrative?

Ryerson Holding Corporation recently reported past first-quarter 2026 results, with sales rising to US$1,566.5 million and net income reaching US$4.5 million, alongside a return to positive earnings per share from continuing operations. On the same day, the company also filed a US$50.22 million shelf registration for 1,800,000 common shares tied to an ESOP-related offering, underscoring its use of equity for employee benefit plans. We will now examine how Ryerson’s return to profitability...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway

Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval. See our latest analysis for Taysha Gene Therapies. The reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...